← Eichor
Study identifier: NCT06072131 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Condition: Peripheral T Cell Lymphoma  ·  Sponsor: Acrotech Biopharma Inc.

PhasePhase 3
Planned participants504
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for part 2 study. Part 2 (Efficacy and Safety): This is a 3 Arm study. Patients with previously untreated PTCL will be randomized 1:1:1 into 1 of 3 treatment groups: 2 experimental treatment groups (Bel-CHOP or Fol-COP) or 1 active comparator treatment group (CHOP). Patients will be treated for up to 6 cycles. The primary objective is to compare the Progression Free Survival of patients with newly diagnosed PTCL treated for up to 6 cycles with Beleodaq (belinostat) in combination with CHOP (Bel-CHOP) or Folotyn (pralatrexate injection) in combination with COP (Fol-COP) to CHOP alone.

This description comes directly from the study's public registry record.

Talk to the study team

Uma Srinivas Atmuri, MPharm, MS  ·  732-917-2420  ·  uatmuri@acrotechbiopharma.com

Always discuss trial participation with your own doctor first.

Locations (69)

University of California, San Francisco FresnoClovis, California, United StatesRecruiting
University of California, Los Angeles Hem/ Onc Clinical Research Unit, Suite 600Santa Monica, California, United StatesRecruiting
University of Colorado School of MedicineAurora, Colorado, United StatesRecruiting
Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System Memorial Cancer InstitutePembroke Pines, Florida, United StatesRecruiting
Norton Cancer InstituteLouisville, Kentucky, United StatesRecruiting
Henry Ford Health SystemDetroit, Michigan, United StatesRecruiting
Rutgers Cancer Institute of New JerseyNew Brunswick, New Jersey, United StatesRecruiting
Valley Cancer AssociatesHarlingen, Texas, United StatesWithdrawn
Houston Methodist HospitalHouston, Texas, United StatesWithdrawn
University of Texas, MD Anderson Cancer CenterHouston, Texas, United StatesRecruiting
Baylor Scott & White Medical Center - TempleTemple, Texas, United StatesRecruiting
The Ottawa HospitalOttawa, Ontario, CanadaRecruiting

+ 57 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06072131